New-Onset Delusions Heralding an Underlying Neurodegenerative Condition: A Case Report and Review of the Literature

Instructions

Click the red REGISTER button to pay the $10 fee and take the posttest
Click here to return to the JCP CME article.

Overview

In this CME journal article, the authors describe a case of new-onset psychosis in a middle-aged woman, review red-flags for a neurodegenerative diagnosis rather than a primary psychotic disorder, and examine the role of genetics.


Read the whole article at psychiatrist.com here:
New-Onset Delusions Heralding an Underlying Neurodegenerative Condition:  A Case Report and Review of the Literature

© Copyright 2020 Physicians Postgraduate Press, Inc.

Target Audience

Psychiatrists

Learning Objectives

Include neurodegenerative disease in the differential diagnosis for any patient presenting with new-onset psychosis and behavioral changes in mid-to-late adulthood

Activity summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Activity opens: 
03/31/2020
Activity expires: 
04/30/2022
Cost:
$10.00
Rating: 
0

CME Background

Articles are selected for credit designation based on an assessment of the educational needs of CME participants, with the purpose of providing readers with a curriculum of CME articles on a variety of topics throughout each volume. Activities are planned using a process that links identified needs with desired results.

CME Objective

After studying this article, you should be able to:

  • Include neurodegenerative disease in the differential diagnosis for any patient presenting with new-onset psychosis and behavioral changes in mid-to-late adulthood

Statement of Need and Purpose

Diagnosing patients who have new-onset psychosis in middle age or older adulthood is challenging due to the overlap with neurodegenerative causes of psychosis. For example, symptoms of behavioral variant frontotemporal dementia (bvFTD) often mimic those of psychiatric disorders and commonly result in misdiagnoses. Failure to identify the cause of psychosis will delay appropriate management and possibly result in unnecessary exposure to antipsychotic drugs. An educational intervention for clinicians is needed to improve awareness of potential causes of dementia-related psychosis and to increase provision of appropriate testing.

Release, Expiration, and Review Dates

This educational activity was published in March 2020 and is eligible for AMA PRA Category 1 Credit™ through April 30, 2022. The latest review of this material was March 2020.

Disclosure of off-label usage

The authors have determined that, to the best of their knowledge, no investigational information about pharmaceutical agents or device therapies that is outside US Food and Drug Administration–approved labeling has been presented in this activity.

Funding/support

No external funding sources were required for this work.

Acknowledgments

The authors thank the patient’s guardian for granting permission to publish this case and for being such a caring friend during the patient’s life.

Patient consent

The patient’s guardian provided consent to publish this case, and information has been de-identified to protect anonymity.

Faculty Affiliation

Emily A. Ferenczi, BM, BCh, PhD*
Department of Neurology, Brigham and Women’s Hospital, and Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts

Michael G. Erkkinen, MD
Department of Neurology, Brigham and Women’s Hospital, and Center for Brain/Mind Medicine, Brigham and Women’s Hospital, Boston, Massachusetts

Mel B. Feany, MD, PhD
Department of Pathology, Brigham and Women’s Hospital, Boston Massachusetts

Barry S. Fogel, MD
Department of Neurology, Brigham and Women’s Hospital, Center for Brain/Mind Medicine, Brigham and Women’s Hospital, and Department of Psychiatry, Brigham and Women’s Hospital, Boston, Massachusetts

Kirk R. Daffner, MD
Department of Neurology, Brigham and Women’s Hospital, and Center for Brain/Mind Medicine, Brigham and Women’s Hospital, Boston, Massachusetts

*Corresponding author: Emily A. Ferenczi, BM, BCh, PhD, Department of Neurology, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114 (eferenczi@partners.org).

Financial Disclosure

All individuals in a position to influence the content of this activity were asked to complete a statement regarding all relevant personal financial relationships between themselves or their spouse/partner and any commercial interest. The CME Institute has resolved any conflicts of interest that were identified. In the past year, Marlene P. Freeman, MD, Editor in Chief of The Journal of Clinical Psychiatry, has received research funding from JayMac and Sage; has been a member of the advisory boards for Otsuka, Alkermes, and Sunovion; has been a member of the Independent Data Safety and Monitoring Committee for Janssen; has been a member of the Steering Committee for Educational Activities for Medscape; and, as a Massachusetts General Hospital (MGH) employee, works with the MGH National Pregnancy Registry, which is sponsored by Teva, Alkermes, Otsuka, Actavis, and Sunovion, and works with the MGH Clinical Trials Network and Institute, which receives research funding from multiple pharmaceutical companies and the National Institute of Mental Health. No member of the CME Institute staff reported any relevant personal financial relationships.

Drs FerencziErkkinenFeanyFogel, and Daffner have no personal affiliations or financial relationships with any commercial interest to disclose relative to the article.

Accreditation Statement

The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

 

 

Credit Designation

The CME Institute of Physicians Postgraduate Press, Inc., designates this journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Price

Cost:
$10.00
Please login or register to take this activity.

Register for free on our site to participate in this and many free CME courses. There is a $10 processing fee for this activity.